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Chromosomal translocations affecting the IGH locus and various oncogene loci are recurrent in many types of
systemic B-cell lymphomas. Hardly any data exist, however, on such translocations in primary cutaneous B-cell
lymphomas (PCBCL). Here, a series of 29 PCBCL was investigated by interphase ﬂuorescence in situ hybridization
with probes for the IGH, MYC, BCL6, and MLT1 loci. None of the six follicle center cell lymphomas and nine
marginal zone lymphomas showed evidence for any translocation affecting these loci. In contrast, 11 of 14 large
B-cell lymphomas of the leg harbored breakpoints in at least one of the loci. Translocations involving the MYC
locus were detected in six cases, ﬁve of them derived from a MYC/IGH juxtaposition and one from a translocation
involving a non-IG gene partner. Rearrangements of the BCL6 locus were detected in ﬁve B-cell lymphomas of the
leg, and involved IGH (two cases), IGL (one case), and non-IG genes (two cases). This study shows that large B-cell
lymphomas of the leg display a pattern of chromosomal translocations similar to their systemic counterparts
whereas primary cutaneous follicle center cell lymphomas and marginal zone lymphomas lack these typical
chromosomal translocations.
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Chromosomal translocations leading to activation of onco-
genes via juxtaposition next to regulatory sequences of one
of the immunoglobulin loci in 14q32 (IGH), 2p12 (IGK), or
22q11 (IGL) are recurrent primary genetic aberrations in
various subtypes of B-cell lymphomas (Willis and Dyer,
2000; Siebert et al, 2001). The so-called Burkitt transloca-
tion t(8;14)(q24;q32) and its variants t(2;8)(p12;q24) and
t(8;22)(q24;q11) targeting the MYC oncogene locus in 8q24
are the hallmark of Burkitt’s lymphoma (BL) and lead to the
deregulated expression of the MYC transcription factor.
Breakpoints in the MYC locus are present in all BL.
Consequently the detection of these changes is mandatory
for the diagnosis of this lymphoma entity (Diebold et al,
2001). The translocation t(14;18)(q32;q21) leading to dereg-
ulation of the apoptosis inhibitor BCL2 is present in
approximately 90% of nodal follicular lymphomas (FL)
(Nathwani et al, 2001). Deregulation of BCL6 either by
juxtaposition next to an IG locus or by promotor substitution
due to a chromosomal translocation affecting band 3q27
can be detected in about 30% of systemic diffuse-large
B-cell lymphomas (DLCBL) (Gatter and Warnke, 2001). BCL6
is a zinc-finger transcriptional repressor required for the
development of germinal centers. Although these aberra-
tions are associated with a certain lymphoma subtype, most
of them are not specific for this entity. In addition to the
examples described above, many other translocations
affecting the IGH locus have been described to occur with
much lower frequency in systemic B-cell lymphomas.
Among them, a t(14;18) cytogenetically identical to that
occurring in FL can lead to activation of the MALT1
oncogene (Sanchez-Izquierdo et al, 2003; Streubel et al,
2003). This gene is also targeted by a recurrent
t(11;18)(q21;q21) present in approximately 30% of systemic
marginal zone lymphomas of MALT type, which leads to
fusion of the MALT1 gene with the apoptosis inhibitor-2
(API2) gene in 18q21 (Dierlamm et al, 1999; Chaganti et al,
2000; Ye et al, 2003). Overall, translocations affecting one IG
locus are estimated to be present in at least half of the nodal
B-cell non-Hodgkin lymphomas.
In contrast to systemic B-cell lymphomas only few data
exist on the presence of recurrent translocations in primary
cutaneous B-cell lymphomas (PCBCL). Various PCR-based
studies have investigated the presence of t(14;18) involving
IGH and BCL2 in PCBCL but yielded contradictory results.
Whereas some studies suggest absence of this transloca-1Share senior authorship.
Abbreviations: BL, Burkitt’s lymphoma; FISH, fluorescence in situ
hybridization; FL, follicular lymphomas; LBCLL, large B-cell
lymphomas of the leg; PCBCL, primary cutaneous B-cell lympho-
mas; PCFCCL, primary cutaneous follicle center cell lymphomas;
PCMZL, primary cutaneous marginal zone lymphomal
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tion (Geelen et al, 1998; Child et al, 2001; Goodland et al,
2002) others could detect IGH/BCL2 juxtaposition in
PCBCL in a variable fraction of the cases (Cerroni et al,
1994; Yang et al, 2000; Aguilera et al, 2001; Mirza et al,
2002; Servitje et al, 2002). Nevertheless, it has to be taken
into account that PCR-based methods for the detection of
t(14;18) frequently result in positive results also in non-
neoplastic tissue samples (Summers et al, 2001; Biagi and
Seymour, 2002). For many other translocations affecting IG
loci, PCR approaches either have not been developed or
are difficult to perform because of the scattering of the
molecular breakpoints or have been shown to work not
reliably. Interphase fluorescence in situ hybridization (FISH)
has been repeatedly shown to overcome these limitations
and to be a robust method for the detection of promiscuous
breakpoints and recurrent translocations (Siebert and
Weber-Matthiesen, 1997). In order to investigate whether
translocation breakpoints highly recurrent in systemic B-cell
lymphomas are also present in PCBCL, we studied a series
of 29 PCBCL by means of interphase FISH with assays
targeting the IGH, MYC, BCL6, and MALT1 loci.
Results
Classification, clinical data as well as relevant results of
immunohistochemical studies of the 29 cases are presented
in Table I.
Translocation breakpoints involving the IGH locus in
chromosome band 14q32 All six cases of PCFCCL, all
nine PCMZL, and seven of 14 LBCLL lacked molecular
cytogenetic evidence for a chromosomal translocation
involving the IGH locus (Table II). The percentage of nuclei
displaying a signal constellation indicating a chromosomal
breakpoint in the IGH locus in these lymphomas ranged
from 0.5% to 3% and was, thus, far below the cutoff level.
From the 14 LBCLL, seven cases contained a significant
percentage of nuclei (40%–77%) with a signal constellation
that did indicate a breakpoint in the IGH locus. Further
molecular cytogenetic analyses indicated the presence
of a translocation t(8;14)(q24;q32) in five and of a
t(3;14)(q27;q32) in two of these seven LBCLL (Fig 1; Table
II). In none of the cases with a breakpoint in the IGH locus a
translocation t(14;18) was detected.
Translocation breakpoints involving the BCL6 locus in
chromosome band 3q27 All PCFCCL and PCMZL as well
as nine of 14 LBCLL lacked evidence for a breakpoint in the
BCL6 locus. The percentage of nuclei with a signal pattern
indicating a BCL6 break never exceeded 1% in these cases.
Five LBCLL displayed a significant proportion of interphase
nuclei (39%–75%) with a signal pattern indicating a break-
point affecting the BCL6 locus. These included the two
cases with t(3;14)(q27;q32) described above as well as
another case in which additional FISH indicated the IGL
locus as BCL6 translocation partner (Table II). In two LBCLL,
the IGH, IGL, and IGK loci were excluded as BCL6 partners.
Overall, Bcl6 was expressed in nine of 22 PCBCL without
BCL6 translocation and in all five LBCLL bearing this
chromosomal change. Focussing on the LBCLL group, Bcl6
was expressed in four of nine cases without BCL6
translocation (case no. 17, 21, 25, and 26) (Tables I and II).
Translocation breakpoints involving the MYC locus in
chromosome band 8q24 All six cases of PCFCCL, all nine
PCMZL, and eight of 14 LBCLL lacked molecular cytoge-
netic evidence for a chromosomal translocation involving
the MYC locus (Table II). The percentage of nuclei displaying
a signal constellation indicating a chromosomal breakpoint
in the MYC locus in these lymphomas never exceeded
2.5% and was, thus, far below the cutoff level. In six LBCLL
a signal pattern indicating a chromosomal breakpoint in the
MYC locus was detected in 48%–74% of the nuclei. These
included the five LBCLL with t(8;14) described above as
well as one additional LBCLL in which further FISH analyses
provided evidence for a non-IG locus as partner. In all the
five cases with t(8;14), immunohistochemical analyses
detected expression of Bcl2. In contrast, expression of
EBER (Epstein–Barr virus-encoded small DNA) was not
detected in any of these cases and CD10 was only weakly
detected in one of them (results not shown). TdTwas absent
in all four t(8;14)-positive LBCLL analyzed whereas only one
of five cases expressed Bcl6. The proportion of cells
staining positive for Ki-67 ranged between 25% and 75%
in the 3 t(8;14)-positive LBCLL studied.
Translocation breakpoints involving the MALT1 locus in
chromosome band 18q21 In none of the 29 PCBCL under
study, FISH provided evidence for a chromosomal break-
point affecting the MALT1 locus. The percentage of nuclei
with a signal pattern indicating a MALT1 breakpoint never
exceeds 2.5% (Table I).
Discussion
In this study, we investigated a series of 29 PCBCL for the
occurrence of chromosomal breakpoints in gene loci
recurrently affected in systemic B-cell lymphomas. Eleven
of the 14 LBCLL cases investigated displayed signal
constellations indicating the presence of a chromosomal
breakpoint in IGH, BCL6, or MYC. In contrast, all six cases
of PCFCCL and all nine cases of PCMZL were devoid of any
molecular cytogenetic evidence for a breakpoint in the IGH,
MYC, BCL6, or MALT1 locus. Thus, with regard to the
presence of chromosomal translocations LBCLL seem to
significantly differ from the other two subtypes of PBCBL
studied herein (11 of 14 vs zero of 15; po0.001; Fisher’s
exact test).
The interphase cytogenetic aberration pattern of LBCLL
resembles that of systemic DLBCL. Breakpoints affecting
the BCL6 locus were detected in five of 14 (36%) LBCLL.
The incidence of BCL6 rearrangements in systemic DLBCL
is assumed to be approximately 30% (Gatter and Warnke,
2001). Remarkably, systemic DLBCL with BCL6 breaks tend
to show an increased frequency of extranodal disease (Offit
et al, 1994). In our series, all five LBCLL with BCL6
translocations expressed the Bcl6 protein whereas four of
nine LBCLL without BCL6 translocation were positive
(p¼0.09, Fisher’s exact test) (Table I). Overall, although
BCL6 translocations did not necessarily lead to enhanced
expression of the protein detectable by immunohistochem-
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istry, there was a significant correlation between Bcl6
expression and presence of BCL6 translocations in PCBCL
(five of five with translocation vs nine of 22 without
translocation; p¼0.04, Fisher’s exact test). It would be
interesting to know whether at all point mutations in BCL6
might be related to the protein expression status in PCBCL
(Lossos et al, 2002). Translocations affecting the IGH locus
were detected in seven of 14 (50%) of the LBCLL and, thus,
also in a similar frequency to systemic DLBCL. Strikingly,
the most frequent translocation partner of the IGH locus
was the MYC gene in 8q24. A signal pattern indicating
t(8;14)(q24;q32) was detected in five of 14 LBCLL. One
additional LBCLL carried a break in the MYC locus not
involving an IG partner. Translocations affecting the MYC
locus, particularly the Burkitt translocation t(8;14), are the
hallmark of BL (Diebold et al, 2001). Nevertheless, these
aberrations are not restricted to this lymphoma subtype,
and recurrently appear in other systemic lymphomas like in
FL transforming to high grade lymphomas (Macpherson
et al, 1999; Akasaka et al, 2000). All five LBCLL with a signal
pattern indicating the presence of t(8;14) lacked typical
Burkitt morphology. Moreover, in contrast to BL these
LBCLL expressed strongly Bcl2 but lacked CD10 as well as
Bcl6 in four of five cases (Table I). The proliferation activity
Table I. Clinical and immunohistochemical data from the patients studied in the present series
Case
number
Gender/age (y)
at diagnosis
Diagnosis
Site of
presentation
Immunohistochemistry
First
therapy Status
Follow-up
time (mo)EORTC WHO CD10 Bcl6 Bcl2
1 M/58 PCFCCL DLBCL Head ND Pos Neg RT Aþ 24
2 F/74 PCFCCL FL Head ND ND Neg RT Aþ 18
3 M/59 PCFCCL FL Back ND Pos Neg RT A0 18
4 F/61 PCFCCL FL Head ND Pos Neg RT A0 21
5 F/54 PCFCCL DLBCL Trunk/gluteal ND Pos Pos CT Aþ 168
6 M/58 PCFCCL FL Trunk ND Pos Neg EX A0 32
7 M/34 PCMZL PCMZL Arms ND Neg Pos EX Aþ 78
8 M/47 PCMZL PCMZL One leg ND Neg Pos EX Aþ 62
9 M/59 PCMZL PCMZL Head ND Neg Pos EX Aþ 27
10 M/63 PCMZL PCMZL Arm ND Neg Neg RT A0 24
11 F/38 PCMZL PCMZL Trunk ND Neg Neg RT A0 13
12 M/35 PCMZL PCMZL Head ND Neg Pos Rit Aþ 18
13 M/44 PCMZL PCMZL Trunk ND Neg Pos RT A0 32
14 F/64 PCMZL PCMZL Two legs ND ND ND EX/AB A0 22
15 M/65 PCMZL PCMZL Trunk ND Neg Neg EX A0 24
16 F/53 LBCLL DLBCL One leg Neg Neg Pos CT Aþ 120
17 F/73 LBCLL DLBCL One leg Neg Pos Pos RT DD 18
18 F/77 LBCLL DLBCL One leg Neg Pos Pos RT A0 51
19 M/69 LBCLL DLBCL One leg Neg Neg Pos RT DD 35
20 F/82 LBCLL DLBCL One leg Neg Pos Pos RT DD 38
21 M/47 LBCLL DLBCL Two legs Neg Pos Pos CT/RT A0 24
22 M/65 LBCLL DLBCL Two legs Neg Neg Pos RT Aþ 60
23 M/70 LBCLL DLBCL Two legs Neg Neg Pos IFN Aþ 28
24 F/80 LBCLL DLBCL One leg ND Pos Pos Ex A0 23
25 F/74 LBCLL DLBCL One leg Neg Pos Pos CT A0 12
26 F/84 LBCLL DLBCL One leg Neg Pos Pos CT A0 19
27 M/89 LBCLL DLBCL One leg Neg Pos Pos CT DD 12
28 F/90 LBCLL DLBCL One leg Neg Pos Pos RT DD 29
29 M/79 LBCLL DLBCL One leg /þ (weak) Neg Pos RT DD 16
PCFCCL, primary cutaneous follicle center cell lymphoma; PCMZL, primary cutaneous marginal zone lymphoma; LBCLL, large B-cell lymphoma of
the leg; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; M, male; F, female; ND, not done; pos, positive; neg, negative; Aþ , alive with
disease; A0, alive without disease; DD, dead from disease; Ex, excision; CT, polychemotherapy; RT, radiotherapy; IFN, interferon a; AB, antibiotics, Rit,
Rituximab.
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detected by Ki-67 staining was between 25% and 75% in
three analyzed cases, which is below the typical level of BL,
where the proliferating cell fraction reaches nearly 100%
(Diebold et al, 2001; Nakamura et al, 2002). Furthermore,
staining for TdT was negative in four analyzed cases and a
latent EBV infection was ruled out by in situ hybridization
with a PNA probe in all five cases. Thus, the diagnosis of a
cutaneous manifestation of BL can be definitely ruled out in
the LBCLL with t(8;14). Remarkably, we and others have
recently shown that LBCLL carry a high load of genomic
imbalances, particularly gains in 18q, 1q, 7, 12q and Xp,
and losses in 6q (Mao et al, 2002; Hallermann et al, 2003),
whereas classical BL mostly show rather simple karyotypes
devoid of many chromosomal changes secondary to the
Burkitt translocation. In summary, many LBCLL display a
genotypic and phenotypic profile similar to that of systemic
DLBCL. The pattern of chromosomal changes including
MYC and BCL6 breaks, which are supposed to be
introduced in a mislead germinal center reaction, along
with the presence of ongoing somatic hypermutation and a
typical gene expression profile suggests at least a major
subset of LBCLL to be derived from germinal center B cells.
The clinical outcome of the LBCLL group was signifi-
cantly worse than the PCFCCL/PCMZL (5 y overall survival
Table II. Chromosomal aberrations in the PCBCL studied herein detected by interphase FISH
Number Diagnosis
Breakpoints (% of cells with rearrangement)
Additional FISH analysesaIGH BCL6 MYC MALT1
1 PCFCCL Neg Neg Neg Neg
2 PCFCCL Neg Neg Neg Neg
3 PCFCCL Neg Neg Neg Neg
4 PCFCCL Neg Neg Neg Neg
5 PCFCCL Neg Neg Neg Neg
6 PCFCCL Neg Neg Neg Neg
7 PCMZL Neg Neg Neg Neg
8 PCMZL Neg Neg Neg Neg
9 PCMZL Neg Neg Neg Neg
10 PCMZL Neg Neg Neg Neg
11 PCMZL Neg Neg Neg Neg
12 PCMZL Neg Neg Neg Neg
13 PCMZL Neg Neg Neg Neg
14 PCMZL Neg Neg Neg Neg
15 PCMZL Neg Neg Neg Neg
16 LBCLL Pos (40.2%) Neg Pos (47.5%) Neg IGH con BCL2  0; IGH con MYC  2 (50%)
17 LBCLL Neg Neg Neg Neg
18 LBCLL Pos (40.0%) Pos (39.1%) Neg Neg IGH con BCL2  0; IGH con BCL6  2 (46%)
19 LBCLL Neg Neg Neg Neg
20 LBCLL Neg Pos (45.5%) Neg Neg IGKc sep IGKt x0, IGLc sep IGLt  1 (45%),
IGL con BCL6  2 (54%)
21 LBCLL Neg Neg Neg Neg
22 LBCLL Pos (49.0%) Neg Pos (47.5%) Neg IGH con BCL2  0; IGH con MYC  2 (66%)
23 LBCLL Pos (45.0%) Neg Pos (53.5%) Neg IGH con BCL2  0; IGH con MYC  2 (66%)
24 LBCLL Neg Pos (41.5%) Neg Neg IGKc sep IGKt x0, IGLc sep IGLt  0
25 LBCLL Pos (50.5%) Neg Pos (55.5%) Neg IGH con BCL2  0; IGH con MYC  2 (62%)
26 LBCLL Neg Neg Pos (52.0%) Neg IGKc sep IGKt x0, IGLc sep IGLt  0, IGH con MYC  0
27 LBCLL Neg Pos (66.0%) Neg Neg IGKc sep IGKt x0, IGLc sep IGLt  0
28 LBCLL Pos (77.0%) Pos (74.5%) Neg Neg IGH con BCL2  0; IGH con BCL6  2 (70%)
29 LBCLL Pos (75.5%) Neg Pos (74.0%) Neg IGH con BCL2  0; IGH con MYC  2 (84%)
aPartial interphase FISH karyotypes indicating the most frequent signal pattern, described according to ISCN1995 (Mitelman, 1995). FISH,
fluorescence in situ hybridization; PCFCCL, primary cutaneous follicle center cell lymphoma; PCMZL, primary cutaneous marginal zone lymphoma;
LBCLL, large B-cell lymphoma of the leg; neg, negative; pos, positive (i.e. break apart pattern); t, telomeric; c, centromeric.
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rate 39% vs 100%; p¼ 0.02), which is in agreement with
previously published reports (Vermeer et al, 1996; Willemze
et al, 1997; Grange et al, 2001). Nevertheless, the
prognostic impact of translocations affecting MYC and
BCL6 in PCBCL could not be properly assessed in the
present series due to the presence of translocations only in
the poor prognosis group and the small sample size, which
prevented multivariate analyses.
All six PCFCCL and all nine PCMZL studied herein
completely lacked evidence for breakpoints in the IGH,
MYC, BCL6, or MALT1 locus. As the tumor cell content in all
cases was more than 30% based on morphology and
immunohistology, it is highly unlikely that the applied
interphase FISH assays known to have a sensitivity of
much less than 10% missed the translocations affecting
one of these loci. Remarkably, recent comparative genomic
hybridization (CGH) studies also suggested a much lower
incidence of genomic imbalances in PCFCCL and PCMZL
than in LBCLL (Mao et al, 2002; Hallermann et al, 2003).
Thus, in agreement with the less aggressive clinical course
(Vermeer et al, 1996; Willemze et al, 1997; Grange et al,
2001), these both subtypes of PCBCL show a much lower
incidence of chromosomal instability than LBCLL. Neither
recurrent chromosomal aberrations nor imbalances have so
far been reported for PCFCCL and PCMZL by cytogenetic
and CGH studies. By FISH the translocation t(14;18), the
hallmark of systemic FL, was neither detected in the present
series of PCFCCL nor in any other PCBCL studied (Kim
et al, 2003). These findings are in agreement with several
(but not all) PCR studies aiming to identify BCL2/IGH
juxtaposition in PCBCL (Child et al, 2001; Goodland et al,
2002). Similarly, breakpoints affecting the MALT1 locus in
18q21, which are recurrent in marginal zone lymphomas of
MALT type, were not observed in any of the PCMZL
investigated. This is in line with a recent study suggesting
t(11;18) involving MALT1 to be absent in 27 MALT
lymphomas of the skin (Ye et al, 2003). Streubel et al
(2003) recently reported the presence of t(14;18) involving
MALT1 in three of 11 cutaneous MALT lymphomas. As two
of theses cases were described as Ann Arbor stage IV, it
remains unclear whether these cases constitute PCMZL.
So far, no recurrent chromosomal aberration has been
identified in PCFCCL and PCMZL that distinguishes these
lymphomas from their systemic counterparts. This contrasts
with the findings in LBCLL where obviously a considerable
overlap with systemic DLBCL exists with regard to the
presence of recurrent genetic aberrations. Nevertheless, it
has to be taken into account that also systemic FL and
Figure1
(A) Interphase nuclei from case 28 hybridized with the LSI IGH break
apart probe (Vysis). The two nuclei at the top display a significant
dissociation of the red and green signals (arrows) indicating the
presence of a translocation affecting the IGH. (B) Interphase nucleus
from case 16 hybridized with the LSI MYC/IGH double fusion probe
(Vysis). The presence of two fused red and green signals (arrows)
indicates that a translocation t(8;14)(q24;q32) juxtaposing the MYC and
IGH loci has taken place. The isolated red and green signals point to
the unrearranged MYC and IGH alleles, respectively. (C) False color
display of an interphase nucleus from case 28 (the same as in A)
hybridized with the triple color BCL6/IGH probe. A probe spanning the
BCL6 breakpoint region labeled with a blue fluorochrome (but shown in
pink) was combined with the LSI IGH break apart probe (Vysis). The
presence of two dissociated red and green signals each colocalizing
with pink dots (arrows) indicates the occurrence of a translocation
t(3;14)(q27;q32) juxtaposing the IGH and BCL6 loci. One isolated pink
signal and one red/green colocalization point to the unaltered BCL6
and IGH alleles, respectively.
CHROMOSOMAL TRANSLOCATIONS IN PCBCL 217123 : 1 JULY 2004
marginal zone lymphomas exist lacking the characteristic
primary chromosomal changes. Future studies including
gene expression profiling have to unravel whether these
subgroups of systemic lymphomas are related to PCFCCL
and PCMZL or whether different pathogenetic mechanisms
underlay the development of these cutaneous B-cell
lymphomas.
Material and Methods
Patients features Fresh frozen biopsies from 29 patients with
PCBCL were collected prior to therapy for diagnostic purpose. The
patients gave informed consent to the biopsies. According to the
criteria of the EORTC classification (Willemze et al, 1997), this
group included six primary cutaneous follicle center cell lympho-
mas (PCFCCL), nine primary cutaneous marginal zone lymphomas
(PCMZL), and 14 large B-cell lymphomas of the leg (LBCLL). The
classification according to the WHO is shown in Table I. At the time
of diagnosis, in all cases lymphoma manifestations were restricted
to the skin, as confirmed by complete staging procedures
including blood analyses, computerized tomography of the chest,
ultrasound of peripheral lymph nodes and the abdomen, and a
negative bone marrow histology. The diagnosis PCBCL was
confirmed by demonstration of clonal IGH gene rearrangement
and/or monotypic light chain expression by immunohistochemistry.
Patients features are also shown in Table I.
Immunohistochemistry Biopsy material was either split or two
neighboring punch biopsies were taken from the same skin lesion.
For FISH one part of the material was snap frozen in liquid nitrogen,
the other part was fixed in 4% buffered formalin, embedded and
cut into 2 mm sections. Besides hematoxylin/eosin and Giemsa
staining, immunohistochemistry was performed. For immunohis-
tochemistry, the sections were dewaxed in xylol (Merck, Darm-
stadt, Germany), rehydrated in decreasing serial dilutions of
ethanol, and stained with antibodies to CD20 (clone L26, Dako,
Glostrup, Denmark), Bcl2 (clone 124, Dako), and to Bcl6 (clone PG-
B6p; Dako). Furthermore, part of the cases were stained with Ki-67
(clone MIB1, Dako), CD10 (clone 56C6, Novocastra, Newcastle-
Upon-Tyne, UK), and TdT (code 004, LavVision/Neomarkers
Fremont). The NexES IHC immunostaining device (Ventana
Medical Systems, Strasbourg, France) was used in combination
with an alkaline phosphatase anti-alkaline phosphatase technique
(APAAP) and Fast Red as substrate according to the manufac-
turer’s instructions (Ventana Medical Systems). When more than
50% of lymphoma cells showed a distinct staining with an
antibody, the case was considered as positive.
Furthermore, latent Epstein–Barr virus infection was studied
using the PNA In Situ Hybridization Detection Kit (code K5201,
Dako) according to instructions of the manufacturer.
Interphase FISH Interphase FISH was performed without knowl-
edge of the histopathologic diagnosis. For FISH, thick cryosections
(60 mm) were mechanically disaggregated and digested in 5%
pepsin solution for 5 min at 371C. Cytospins were prepared and the
cells were fixed for 10 min in 1% paraformaldehyde solution,
dehydrated in graded ethanol series, and air-dried at room
temperature. Directly labeled probes flanking the IGH (LSI IGH
break apart probe, Vysis, Downers Grove, Illinois), IGK, IGL (break-
apart probes, described in Martin-Subero et al, 2002b), MYC (LSI
MYC break-apart probe, Vysis), BCL6 (LSI BCL6 break apart
probe, Vysis), and MALT1 (LSI MALT1 break-apart probe, Vysis;
and Dierlamm et al, 1999) loci were applied to study the
occurrence of chromosomal translocations affecting those genes.
The LSI IGH/MYC/CEP8 and LSI IGH/BCL2 dual fusion probes (all
from Vysis) were applied to assess the presence of the t(8;14) and
t(14;18) chromosomal translocations, respectively. For the detec-
tion of the t(3;14) (IGH/BCL6) and t(3;22) (IGL/BCL6), the above
quoted IGH and IGL break-apart probes were combined with a
probe spanning the BCL6 breakpoint region (Sanchez-Izquierdo
et al, 2001) differentially labeled with diethyl aminomethyl coumarin
(DEAC, blue fluorescence). Non-commercial probe preparation
and FISH were performed according to previously published
protocols (Martin-Subero et al, 2002a, b).
Results were evaluated using a fluorescence microscope
(Axioplan or Axioskop, Zeiss, Go¨ttingen, Germany) equipped with
the appropriate filter sets and connected to a charge coupled
device camera. Evaluation of at least 200 nuclei was attempted per
cytospin preparation whenever possible.
Evaluation criteria and diagnostic cutoffs for the applied
double-color FISH probes have been determined recently. For all
these assays, the cutoffs were far below 10% applying appropriate
evaluation criteria (Martin-Subero et al, 2003). Based on these
controls and the estimated tumor cell content in the PCBCL
samples studied herein (at least 30% based on morphology and
immunohistology) the diagnostic cutoff was uniformly set for all
probes at 10% (Montesinos-Rongen et al, 2002; Martin-Subero
et al, 2002b, 2003).
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